Aromatase inhibitors in adjuvant endocrine treatment of breast cancer: ending the debate of sequence or upfront?——interpretation of BIG 1-98 clinical trial
10.3760/cma.j.issn.1006-9801.2010.03.003
- VernacularTitle:乳腺癌芳香化酶抑制剂辅助内分泌治疗:序贯或初始应用争论的结束?——解读BIG 1-98临床试验
- Author:
Xiaosong CHEN
;
Kunwei SHEN
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Aromatase inhibitors;
Neoadjuvant therapy
- From:
Cancer Research and Clinic
2010;22(3):152-154
- CountryChina
- Language:Chinese
-
Abstract:
The third generation of aromatase inhibitors (AI) play an important role in the adjuvant treatment of hormonal positive postmenopausal breast cancer. Compared with tamoxifen, either upfront or sequential using of Al can both significantly improve the outcome of breast cancer patients. However, there is a continuous debate of sequence or upfront usage of Al in clinical applications. With the publication result of BIG 1-98 clinical trial and interpretation of the data, we can further recognize and optimize the usage of Al in breast cancer treatment.
